What Oisin Biotechnologies does

Oisín Biotechnologies is a Seattle-based, privately held biotechnology company developing a new class of redosable genetic medicines targeting the biology of aging. The company's core technology is the Fusogenix Proteo-Lipid Vehicle (PLV), a proprietary non-viral delivery platform that fuses directly with target-cell membranes to deliver both DNA and RNA payloads. Unlike conventional viral vectors, Fusogenix PLV enables safe repeated dosing, extensive extrahepatic biodistribution reaching tissues throughout the body, and accommodation of large cargoes. The platform's mechanism was peer-reviewed and published in Cell in 2024.

The company applies this single delivery platform across three pipeline areas: (1) targeted fat removal, a precision therapy for selective fat cell elimination spanning rare disease and non-invasive fat reduction markets; (2) muscle building, genetic therapies for skeletal muscle growth and preservation with both aesthetic applications and systemic use cases pairing with GLP-1 drugs to preserve lean muscle mass; and (3) a deeper longevity biology pipeline targeting klotho, extracellular-matrix remodeling, mitochondrial function, cellular reprogramming, and clearance of senescent cells. The company explicitly pursues indications "regulators already understand" to establish a stepwise path to approval.

Oisín is a pre-revenue company funded by venture capital. It has raised approximately $32-34 million across multiple rounds, including a $5 million seed led by Althea Group (2021), a $15 million Series A first close led by AbbVie Ventures (2024), and a $10 million round from Healthspan Capital (2025). The company operates with 11-50 employees from its Seattle headquarters and San Diego R&D laboratory. Leadership includes CEO and founder Matthew Scholz, CSO John Lewis, COO Eric Garcia, and a board chaired by Gary Hudson with representation from AbbVie Ventures and Methuselah Foundation. Future revenue is intended to come from therapeutic product sales upon regulatory approval, with clinical trials serving as the initial distribution channel.

Name

Oisin Biotechnologies

Legal name

Oisín Biotechnologies

Website

https://oisinbio.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

11–50 employees

Short description

Oisín Biotechnologies is a preclinical Seattle-based biotech developing the Fusogenix PLV non-viral delivery platform to create redosable genetic medicines for age-related diseases, including targeted fat removal, muscle building, and longevity biology therapies.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Gene Therapy Delivery Devices & Administration Systems (catheters, intrathecal, ocular delivery) (HLAAACAL)

Keywords

• Genetic medicines
• Biopharmaceutical development
• Non-viral gene delivery
• Longevity therapeutics
• Age-related disease research

Headquarters

HQ city

Seattle

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Genetic Medicine Pipeline: Pre-revenue biotech company developing genetic medicines for age-related diseases. Revenue will be generated through therapeutic product sales upon regulatory approval.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

Oisín Biotechnologies develops a new class of redosable genetic medicines that target the biology of aging, leveraging its proprietary Fusogenix Proteo-Lipid Vehicle (PLV) non-viral delivery platform. The company is building a pipeline of DNA and RNA therapies spanning targeted fat removal, muscle preservation and growth, and longevity biology candidates for age-related diseases.

Product overview

Oisín Biotechnologies is developing a new class of genetic medicines targeting the biology of aging. The company is built on the Fusogenix Proteo-Lipid Vehicle (PLV) platform, a non-viral delivery technology that enables redosable DNA and RNA therapies with extensive tissue distribution beyond the liver. The pipeline applies this single delivery platform across multiple therapeutic areas: Targeted Fat Removal (precision fat cell elimination), Muscle Building Therapy (genetic therapies for skeletal muscle growth and preservation), and a Longevity Biology Pipeline targeting fundamental drivers of aging including klotho, mitochondrial function, cellular reprogramming, and senescent cell clearance.

Differentiator

Problem solved

Functional benefit

Products and services

• Fusogenix Proteo-Lipid Vehicle (PLV) Platform A non-viral delivery technology that fuses directly with target-cell membranes to deliver both DNA and RNA payloads, enabling redosable genetic therapies with extensive extrahepatic biodistribution beyond the liver and large payload capacity. Serves as the foundational platform for the company's therapeutic pipeline targeting age-related diseases.
• Targeted Fat Removal Therapy Pre-clinical precision genetic therapy that selectively eliminates unwanted fat cells while sparing surrounding tissue, intended for non-surgical body contouring and rare-disease fat-reduction applications.
• Muscle Building Therapy Pre-clinical genetic therapy that drives targeted growth and preservation of skeletal muscle, initially for local aesthetic applications and potentially for systemic age-related muscle loss, including pairing with GLP-1 drugs to preserve lean muscle mass.
• Longevity Biology Pipeline Pre-clinical pipeline of genetic therapies targeting fundamental drivers of aging including klotho and other longevity-associated factors, extracellular-matrix remodeling, mitochondrial function, cellular reprogramming, and clearance of senescent cells.

Quantifiable outcome

• Fusogenix PLV enables delivery to tissues throughout the body, not just the liver
• +1 more outcomes

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Unity Biotechnology: Pioneer senolytic biotech developing small molecules and biologics to selectively eliminate senescent cells for age-related diseases. Directly comparable therapeutic area (senolytics) and longevity-medicine positioning, though Unity uses small-molecule rather than genetic-medicine modalities.
• BioAge Labs: Clinical-stage biotech identifying drug targets through aging-biology research and developing therapeutics for age-related diseases. Comparable in applying longevity biology to drug development and in targeting age-related indications, with publicly disclosed clinical-stage assets.
• Generation Bio: Genetic medicines company developing non-viral lipid nanoparticle-based delivery of DNA and RNA payloads for rare and other diseases. Most direct competitor on the non-viral delivery technology axis, with shared strategic positioning around extrahepatic biodistribution and redosability.
• NewLimit: Biotech developing epigenetic reprogramming therapies to restore youthful function in aged cells, founded by Brian Armstrong. Directly comparable longevity-medicine thesis targeting fundamental drivers of aging using genetic/epigenetic interventions.
• Verve Therapeutics: Clinical-stage genetic medicines company developing in vivo gene-editing therapies for cardiovascular disease. Comparable in pursuing in vivo genetic medicines for cardiometabolic and age-related indications, though using base editing rather than DNA/RNA payload delivery.
• AAVantgarde Bio: Clinical-stage gene therapy company developing novel AAV-based delivery platforms to overcome payload-size and tissue-targeting limitations. Directly comparable mission of solving genetic-medicine delivery bottlenecks, though focused on viral vectors rather than non-viral PLV.

Broad incumbents

• Altos Labs: Well-capitalized (>$3B raised) longevity biotech pursuing cellular rejuvenation programming to restore cell health and reverse disease. Comparable mission and longevity-biology focus, but operates at far larger scale and broader scope than Oisín's focused delivery-platform approach.
• Calico Life Sciences: Alphabet-backed longevity research organization developing interventions to counteract aging and associated diseases. Comparable longevity-medicine mission with significantly greater resources, broader portfolio, and longer R&D horizons.

Emerging players

• Insilico Medicine: AI-driven drug discovery company applying generative AI and deep aging-biology research to develop therapeutics for age-related diseases. Comparable longevity focus with differentiated AI-discovery approach rather than genetic-medicine delivery.
• Elixirgen Therapeutics: Clinical-stage biotech developing genetic medicines for aging-related and rare diseases using ZSCAN4-based cell-engineering technology. Comparable niche-stage longevity-medicine positioning and genetic-medicine modality, though with a different delivery/therapeutic approach.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/oisin-biotechnologies

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds6 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Oisin Biotechnologies